Prescription Drug Affordability Review Board

Colorado Prescription Drug Affordability Review Board & Advisory Council

​To receive PDAB and PDAAC updates directly in your inbox, click the button below. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.

Sign up for Division Notifications

PDAB Overview

Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175, is a Type-1 Board within the Division of Insurance that will have the authority to review prescription drug costs and evaluate their impact on Coloradans. The Board may then recommend ways to address those costs and may set an upper payment limit for certain drugs. The Board has appointed a multi-stakeholder Advisory Council to provide input to the Board to ensure its work is informed by a variety of stakeholders.

Meeting Recordings

Upcoming Meetings

PDAB Meeting: Friday, June 23 at 10 am MT    

Register for June 23 PDAB Meeting

PDAAC Meeting & Dashboard Walkthrough: Friday, June 9 at 1 pm MT

Register for June 9 PDAAC Meeting

Stakeholder Meeting: Wednesday, June 14 at 5:30 pm MT

Register for June 14 Stakeholder Meeting 

Questions & Accessibility

Questions about the Prescription Drug Affordability Board and Advisory Council can be sent to dora_ins_pdab@state.co.us.

We are committed to providing equal access to our meetings for all participants. If you would like to request an accommodation to attend a Board or Advisory Council meeting, please contact us at dora_ins_pdab@state.co.us with your request by the close of business at least one week in advance of a meeting.



The Prescription Drug Affordability Board (PDAB) is a 5 member Type-1 Board tasked with the following statutory duties:

  • Identify drugs that may be subject to an affordability review;
  • Conduct affordability reviews on selected eligible drugs;
  • Determine whether a prescription drug is unaffordable for Colorado consumers;
  • If a drug is found to be unaffordable, the Board may set an upper payment limit;
  • Make policy recommendations to the General Assembly.
PDAB Materials

PDAB Meeting Materials

Rules, Policies, & Written Testimony

Board Members

The Governor appointed the following Prescription Drug Affordability Board Members on September 27, 2021:


The Board appointed the 15 member Prescription Drug Affordability Advisory Council (PDAAC) to provide stakeholder input on prescription drug affordability. All PDAAC members meet statutory requirements for composition, geographic representation, and subject matter expertise. 

To the extent possible, the Board appointed members who have experience serving underserved communities and who reflect the state’s diversity in terms of race, immigration status, income, disability, age, gender identity, and geography.

PDAAC Materials

PDAAC Meeting Materials


Council Members
  • Kim Bimestefer Executive Director of HCPF
  • Gail deVore representing health care consumers
  • Sarita Parikh representing health care consumers
  • Edward A. Dauer, LL.B., M.P.H. representing statewide health care advocacy organizations
  • Kimberley Jackson, DO representing consumers with chronic diseases and PDAAC Chair 
  • Maria Fenwick representing a labor union
  • Nathan Wilkes representing employers
  • Chad Friday representing carriers
  • Marc Reece representing pharmacy benefit managers
  • Thomas Tobin, MD, MBA representing health care professionals with prescribing authority
  • R. Brett McQueen, PhD representing an organization that researches prescription drugs
  • Katelin Lucariello MPH representing manufacturers of brand name drugs
  • Neal Miller representing manufacturers of generic drugs
  • Andrew Gonzales, PharmD representing pharmacists
  • Jason Atlas, RPh, MBA representing wholesalers 


Learning Series & Resources

Slides and recordings for the five part Prescription Drug Affordability Learning Series can be found below.

Learning Series 1: Data Deep Dive

View Data Deep Dive

Learning Series 2: Patient Perspectives

View Patient Perspectives

Learning Series 3: Pharmaceutical Supply Chain Panel

View Pharmaceutical Supply Chain Panel

Learning Series 4: Comparative Effectiveness & Affordability

View Comparative Effectiveness & Affordability

Learning Series 5: Prescription Drug Affordability Efforts in Colorado & Other States

View Prescription Drug Affordability Efforts in Colorado & Other States


Frequently Asked Questions

SB21-175 Text

Reducing Prescription Drug Costs in Colorado, 2nd Edition

CIVHC Top 100 Brand and Generic Commercial Payer Prescription Drugs

Conflict of Interest Information

PDAB's Conflict of Interest Policy

Information required to be disclosed pursuant to §10-16-1402(3)(d) will be contained here.